Sandoz has confirmed the European launch of a high-concentration 100mg/ml version of its Hyrimoz (adalimumab) biosimilar rival to Humira, following approval by the European Commission earlier this year.
Sandoz Launches High-Concentration Adalimumab In Europe
Plans To ‘Progressively’ Roll Out 100mg/ml Version Of Hyrimoz Biosimilar To Humira
Sandoz has launched the high-concentration version of its Hyrimoz adalimumab biosimilar rival to Humira in Europe.
More from Biosimilars
• By
Partnering opportunities, paused marketing, approvals, litigations, and many more. Formycon sets out the agenda for 2025, after seeing a bumpy start to the year.
• By
Four key areas for policy reform were identified by industry association Medicines for Europe at its biosimilars conference in early April, as sector chair Isabell Remus set out the importance of removing barriers to biosimilar competition.
• By
Samsung Bioepis and Teva have provided clarity on the pricing of their Epysqli biosimilar to Soliris in the US, as the firms launched only the second rival to the rare diseases treatment.
• By
The EMA’s latest move towards a more streamlined process for biosimilar registration in Europe was the hottest topic at last week’s annual biosimilars conference held by Medicines for Europe in Amsterdam. Generics Bulletin discusses the new draft reflection paper and its significance for industry, reports on reactions from the event, and reveals the next steps unveiled by EMA officials.